Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
idasanutlin + venetoclax + obinutuzumab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination therapy consisting of three agents: - **Idasanutlin**: a small molecule MDM2 antagonist that disrupts the interaction between MDM2 and p53, leading to activation of the p53 pathway and apoptosis in cancer cells with wild-type p53. - **Venetoclax**: a small molecule BCL-2 inhibitor that triggers apoptosis in malignant lymphocytes by inhibiting BCL-2, an anti-apoptotic protein. - **Obinutuzumab**: a type II glycoengineered anti-CD20 monoclonal antibody that elicits B cell lysis through direct cytotoxicity and immune effector mechanisms. This regimen is being investigated for use in patients with relapsed or refractory follicular lymphoma (FL). The therapeutic hypothesis is that dual pathway targeting of apoptosis (MDM2-p53 and BCL2) combined with anti-CD20-mediated B cell depletion may enhance efficacy over single-agent or doublet regimens. The combination is currently under clinical evaluation in early-phase studies for relapsed/refractory follicular lymphoma[1].
- Other names
- idasanutlin + venetoclax + obinutuzumab
02
Targets
Beyond the preview
Go deeper on idasanutlin + venetoclax + obinutuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on idasanutlin + venetoclax + obinutuzumab.